Lessons learnt after the introduction of the seven valent-pneumococcal conjugate vaccine toward broader spectrum conjugate vaccines

Biomedical Journal

Volumn 35, Issue 6, 2012, Pages 450-456

  Falup Pecurariu, Oana ^a  

^a TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

Author keywords

acute otitis media; children; community acquired pneumonia; invasive pneumococcal disease; Pneumococcal conjugated vaccine (PCV7); vaccine serotypes

Indexed keywords

CEFOTAXIME; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE CARRIER; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; HERD IMMUNITY; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MASS IMMUNIZATION; NONHUMAN; PHARYNX DISEASE; PNEUMOCOCCAL INFECTION; REVIEW; RISK REDUCTION; SEROTYPE;

ANIMALS; HUMANS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; UNITED STATES; VACCINES, CONJUGATE;

EID: 84883246321     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.104409     Document Type: Review

References (67)

1. Dagan R, Greenberg D, Jacobs MR, Lane Phillips B. Pneumococcal Infections. Textbook of Pediatric Infectious Diseases. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan S, editors. Vol. 1, 6th ed. Philadelphia: Saunders Elsevier; 2009. p. 1288-342.
2. CDC. Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49; RR-9).
3. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007;298: 1772-8. (Pubitemid 47598445)
4. Obando I, Muñoz-Almagro C, Arroyo LA, Tarrago D, Sanchez-Tatay D, Moreno-Perez D, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 2008;14: 1390-7.
5. Bekri H, Cohen R, Varon E, Madhi F, Gire R, Guillot F, et al. Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France. Arch Pédiatr 2007;14: 239-43. (Pubitemid 46357614)
6. Hortal M, Sehabiague G, Camou T, Iraola I, Estevan M, Pujadas M. Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations. J Pediatr 2008;152: 850-3.
7. Copelovitch L and Kaplan SB. Streptococcus pneumoniae -associated hemolytic uremic syndrome: classification and emergence of serotype 19A. Pediatrics 2010;125:e174-82.
8. Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007;151: 140-4. (Pubitemid 47069411)
9. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348: 1737-46. (Pubitemid 36514704)
10. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009;49: 205-12.
11. Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal vaccine. Pediatr Infect Dis J 2001;20: 1105-7. (Pubitemid 34016419)
12. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201: 32-41.
13. Flannery B, Schrag S, Bennett NM, Lynfield R, Harrison LH, Reingold A, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004;291: 2197-203. (Pubitemid 38608168)
14. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease- United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54: 893-7.
15. Lepoutre A, Varon E, Georges S, Gutman L, Levy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal disease in France, 2001-2006. Available from: http://www.eurosurveillance. org/images/dynamic/EE/V13N35/ art18962.pdf) [Last accessed on 2012 Jan 27].
16. Jardine A, Menzies RI, McIntyre P. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010;7: 607-12.
17. Centers for Disease Control and Prevention, Prevention of Pneumococcal disease among infants and children- use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Imunization Practices (ACIP) MMWR 2010, 59 (No.RR -11): 1-19.
18. Picazo J, Ruiz-Contreras J, Hernandez B, Sanz F, Gutierrez A, Cercenado E, et al. Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: a 2-year (2007-2009) laboratory based surveillance in Madrid. Vaccine 2011;29: 1770-6.
19. Picazo J, Ruiz-Contreras J, Casado- Flores J, Giangaspro E, Del Castillo F, Hernández-Sampelayo T, et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 2011;18: 89-94.
20. Weatherholtz R, Millar EV, Moulton LH, Reid R, Rudolph K, Santosham M, et al. Invasive pneumococcal disease a decade after pneum-ococcal conjugate vaccine use in an American Indian population at risk for disease. Clin Infect Dis 2010;50: 1238-46.
21. Hanquet G, Kissling E, Fenoll A, George R, Lepoutre A, Lernout T, et al. Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis 2010;16: 1428-39.
22. Kaplan SL, Barson WJ, Lin PL, Stovall SH, Bradley JS, Tan TQ, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125: 429-36.
23. Aguilar SI, Brito MJ, Goncalo-Marques J, Melo-Cristino J, Ramirez M. Serotypes 1, 7F and 19A became the leading cause of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use. Vaccine 2010;28: 5167-73.
24. Gertz RE Jr, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, et al. Increased penicillin non susceptibility of non vaccine serotype invasive pneumococci other than 19A and 6A in the post-7-valent conjugate vaccine era. J Infect Dis 2010;201: 770-5.
25. Techasaensiri C, Messina AF, Katz K, Ahmad N, Huang R, McCracken GH Jr. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotype-s of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immuni-zation in Dallas, Texas. Pediatr Infect Dis J 2010;29: 294-300.
26. Hansen J, Black S, Shinefield H, Cherian T, Benson J, Fireman B, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organiziation standar-dized interpretation of chest radiographs. Pediatr Inf Dis J 2006;25: 779-81. (Pubitemid 44325778)
27. Madhi SA, Albrich W. WHO guidelines for treatment of severe pneumonia. Lancet 2007;370: 386-7. (Pubitemid 47189672)
28. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, et al. Efficacy of nine valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: Randomised, double blind, placebo controlled trial. Lancet 2005;365: 1139-46. (Pubitemid 40417563)
29. O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven valent conjugate pneumococcal vaccine in American Indian children: Group randomised trial. Lancet 2003;362: 355-61. (Pubitemid 36945058)
30. Lucero MG, Nohynek H, Williams G, Tallo V, Simões EA, Lupisan S, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: A randomized, double blind, placebo controlled trial. Pediatr Infect Dis J 2009;28: 455-62.
31. Tregnaghi MW, Saez-Llorens X, Lopez P, Abate H, Smith E, Posleman A, et al. Evaluating the efficacy of 10-valent Pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) against community-acquired pneumonia in Latin America. The 29th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). The Hague, The Netherland, 7-11 June 2011, Abstract 1411.
32. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006;118: 865-73. (Pubitemid 46090026)
33. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008;121: 253-60. (Pubitemid 351198446)
34. Hausdorff WP, Felkin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005;5: 83-93. (Pubitemid 40174779)
35. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 2007;25: 2406-12. (Pubitemid 46366120)
36. Ho PL, Chiu SS, Chow FK, Mak GC, Lau YL. Paediatric hospitalization for pneumococcal diseases preventable by the 7-valent pneumococcal conjugate vaccine in Hong Kong. Vaccine 2007;25: 6837-41. (Pubitemid 47391110)
37. Jefferson T, Ferroni E, Curtale F, Giorgi Rossi P, Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis 2006;6: 405-10. (Pubitemid 43949138)
38. Bender JM, Ampofo K, Korgenski K, Daly J, Pavia AT, Mason EO, et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter ? Clin Infect Dis 2008;46: 1346-52. (Pubitemid 351589931)
39. Tyrrell G, Lovgren M, Kellner J, Grimsrud K, Hoang L, Patrick D, et al. Serotype invasive Pneumococcal Investig. Team 2008. A large outbreak of invasive Streptococcus pneumoniae serotype 5 in western Canada. Presented at the ISPPD-6, Reykjavik, Iceland, 8-12 Jun 2008, Abstract Book, p. 50 (S05-O3).
40. Leimkugel J, Adams Forgor A, Gagneux S, Pflüger V, Flierl C, et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in Northern Ghana with features that are characteristisc of Neisseria meningitidis meningitis epidemics. J Infect Dis 2005;192: 192-9. (Pubitemid 40993388)
41. Yaro S, Lourd M, Traoré Y, Njanpop-Lafourcade BM, Sawadogo A, Sangare L, et al. Epidemiological and molecular characte-ristics of a highly lethal pneumococcal men-ingitis epidemic in Burkina Faso. Clin Infect Dis 2006;43: 693-700. (Pubitemid 44330730)
42. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumo-coccal parapneumonic empyema. Pediatr Inf-ect Dis J 2006;25: 250-4. (Pubitemid 43379067)
43. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: A time-series analysis. Lancet 2007;369: 1179-86. (Pubitemid 46527876)
44. Greenberg D, Givon-Lavi N, Newman N, Bar-Ziv J, Dagan R. Nasopharyngeal Carriage of Individual S. pneumoniae Serotypes during Pediatric Pneumonia as a Means to Estimate Serotype Disease Potential. Pediatr Infect Dis J 2011;30: 227-33.
45. Patrzałek M, Albrecht P, Sobczynski M. Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland. Eur J Clin Microbiol Infect Dis 2010;29: 787-92.
46. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pnenumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011;2:e00309-10.
47. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19: 187-95. (Pubitemid 30167436)
48. Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344: 403-9. (Pubitemid 32128672)
49. Grijalva CG, Poehling KA, Nuorti JP, Zhu Y, Martin SW, Edwards KM, et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 2006;118: 865-73. (Pubitemid 46090026)
50. Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2009;28:e271-5.
51. Jardine A, Menzies RI, Deeks SL, Patel MS, McIntyre PB. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009;28: 761-5.
52. Poehling KA, Szilagyi PG, Grijalva CG, Martin SW, LaFleur B, Mitchel E, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007;119: 707-15. (Pubitemid 46556669)
53. Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, et al. Collaborative Group for Pneumococcal Vaccination in Liguria. Vaccine 2009;27: 3459-62.
54. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008;121: 253-60. (Pubitemid 351198446)
55. Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009;302: 758-66.
56. Hoberman A, Paradise JL, Shaikh N, Greenberg DP, Kearney DH, Colborn DK, et al. Pneumococcal resistance and serotype 19A in Pittsburgh-area children with acute otitis media before and after introduction of 7-valent pneumococcal polysaccharide vaccine. Clin Pediatr 2011;50: 114-20.
57. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002;185: 927-36. (Pubitemid 34274436)
58. O'Brien KL, Bronsdon M, Carlone GM, Facklam RR, Schwartz B, Reid RR, et al. Effect of a seven valent pneumococcal conjugate vaccine on nasopharyngeal (NP) carriage among native American infants. Pediatric Academic Societies Annual Meeting. Pediatr Res 2001;49:Abstract 1463, 256A.
59. Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002;185: 927-36. (Pubitemid 34274436)
60. Vestrheim DF, Høiby EA, Aaberge IS, Caugant D. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010;17: 325-34.
61. Jacobs MR, Dagan R, Bajaksouzian S, Windau AR, Porat N. Validation of Factor 6d Antiserum for Serotyping Streptococcus pneumoniae Serotype 6C. J Clin Microbiol 2010;48: 1456-7.
62. Millar EV, Pimenta FC, Roundtree A, Jackson D, Carvalho Mda G, Perilla MJ, et al. Pre and post conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis 2010;51: 1258-65.
63. Porath N, Park IH, Nahm MH, Dagan R. Differential Circulation of Streptococcus pneumoniae Serotype 6C Clones in Two Israeli Pediatric Populations. J Clin Microbiol 2010;48: 4649-51.
64. Calix JJ, Dagan R, Pelton SI, Porat N, Nahm MH. Differential occurence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of oathogen microevolution. Clin Infect Dis 2012;54: 794-9.
65. Hanage WP, Bishop CJ, Huang SS, Stevenson AE, Pelton SI, Lipsitch M, et al. Carried pneumococci in Massachusetts children: The contribution of clonal expansion and serotype switching. Pediatr Inf Dis J 2011;30: 302-8.
66. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable haemophilus influenzae: A randomised double blind efficacy study. Lancet 2006;367: 740-8. (Pubitemid 43326292)
67. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, part I. Clin Infect Dis 2000;30: 100-21. (Pubitemid 30067069)